Glucagon is the key factor in the development of diabetes
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiology of Insulin In Man: The Banting Memorial Lecture 1971
Cahill, G. F. (1971) · Diabetes · doi:10.2337/diab.20.12.785 · Cited by 356
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 2×
“These studies suggest that glucagon is essential for hyperglycaemia in type 1 diabetes and that blocking glucagon action prevents deadly metabolic and clinical derangements [5, 6] (Table 1).”
Self-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327 · cited 2×
“NOD mice [10] Recombinant leptin Non-diabetic”
Self-citationHypertrophy and hyperplasia of somatostatin-containing D-cells in diabetes.
Orci, L., Baetens, D., Rufener, C., Amherdt, M., Ravazzola, M., Studer, P., Malaisse-Lagae, F., & Unger, R. H. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.4.1338 · Cited by 255 · cited 1×
“In contrast to the lack of beta cells in islets of type 1 diabetic patients, type 2 diabetic patients have a few remaining beta cells [13].”
Self-citationThe Banting Memorial Lecture 1975: Diabetes and the Alpha Cell
Unger, R. H. (1976) · Diabetes · doi:10.2337/diab.25.2.136 · Cited by 234
Self-citationGlucagon: Role in the Hyperglycemia of Diabetes Mellitus
Dobbs, R., Sakurai, H., Sasaki, H., Faloona, G., Valverde, I., Baetens, D., Orci, L., & Unger, R. (1975) · Science · doi:10.1126/science.1089999 · Cited by 229 · cited 1×
“isation of diabetes as a bihormonal disease [3] in which hepatic overproduction of fuel is caused by glucagon excess rather than directly by insulin deficiency [4].”
Self-citationConarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Hyperglucagonemia in diabetic ketoacidosis
Müller, W. A., Faloona, G. R., & Unger, R. H. (1973) · The American Journal of Medicine · doi:10.1016/0002-9343(73)90083-1 · Cited by 220 · cited 1×
“diabetes in humans and animals is accompanied by absolute or relative hyperglucagonaemia [1, 2], which led to the character-”
Self-citationMaking insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219 · cited 2×
“In addition, in contrast to insulinmonotherapy, leptin lowers both lipogenic and cholesterologenic transcription factors and enzymes and reduces plasma and tissue lipids [10, 11].”
Self-citationIs HbA1c Affected by Glycemic Instability?
Derr, R., Garrett, E., Stacy, G. A., & Saudek, C. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2728 · Cited by 152
Cited by
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“The pros and cons of antagonizing glucagon action for the treatment of diabetes have recently also been highlighted in several excellent review articles (184, 381, 596), and some even suggest that hyperglucagonemia rather than insulin deficiency is the key factor in the pathogenesis of diabetes (381, 596).”
BackgroundFeeding Rhythms and the Circadian Regulation of Metabolism
Pickel, L., & Sung, H.-K. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00039 · Cited by 255
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Mistimed food intake and sleep alters 24-hour time-of-day patterns of the human plasma proteome
Depner, C. M., Melanson, E. L., McHill, A. W., & Wright, K. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714813115 · Cited by 122
“However, excess glucagon is a key factor contributing to diabetes risk (48) and therefore must be tightly regulated.”
BackgroundGut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.313648 · Cited by 64
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Heterogeneous alpha-cell population modeling of glucose-induced inhibition of electrical activity
Montefusco, F., Cortese, G., & Pedersen, M. G. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.110036 · Cited by 13
Metadata
- Authors
- Lee, Y. H., Wang, M.-Y., Yu, X.-X., & Unger, R. H.
- Venue
- Diabetologia
- Published
- 2016-04-26
- Volume
- 59
- Issue
- 7
- Pages
- 1372-1375
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2342578893
- Cited by
- 166
- References
- 16
- FWCI
- 19.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.